Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), has presented positive...

The Foundation recently hosted a workshop to discuss the state of the field, current challenges, and the road forward for using focused ultrasound to treat Alzheimer’s disease (AD). The meeting took place...

Hong Chen, PhD, her co-senior author Arash Nazeri, MD, an assistant professor of radiology at the School of Medicine’s Mallinckrodt Institute of Radiology, and their research team at Washington University...

A Charlottesville-based pharmaceutical company that recently began clinical trials of its Alzheimer’s treatment hit the stock market Thursday with an initial public offering it hopes will raise about $160 million.